Antibody-drug conjugate · Immune activation, directed at CD19 · developed by AbbVie
ABBV-31 (ABBV-319) is an antibody drug conjugate of an afucosylated IgG1 antibody binding the B-cell surface protein CD19, linked to a glucocorticoid receptor modulator payload. The antibody engages antibody-dependent cellular cytotoxicity, and the payload delivered into CD19-expressing cells inhibits glucocorticoid receptor-driven expression of proliferative and anti-apoptotic genes. It is being studied in systemic lupus erythematosus and dry eye syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06977724 | Phase 1 | Dry Eye Syndrome | Recruiting | ABBV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dry Eye SyndromeSystemic Lupus Erythematosus
See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABBV catalysts and pipeline →